These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32739474)

  • 21. Comparison of novel intrinsic versus conventional antitachycardia pacing for ventricular tachycardia among implantable cardioverter-defibrillator recipients.
    Yanagisawa S; Inden Y; Sato Y; Watanabe R; Goto T; Kondo S; Tachi M; Iwawaki T; Yamauchi R; Hiramatsu K; Shimojo M; Tsuji Y; Shibata R; Murohara T
    J Cardiovasc Electrophysiol; 2024 Apr; 35(4):821-831. PubMed ID: 38424678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arrhythmogenicity of anti-tachycardia pacing in patients with implantable cardioverter defibrillator.
    Awad SS; Azeez EF; Taha MO; El-Naggar WM; El-Damaty A
    Egypt Heart J; 2023 Jun; 75(1):44. PubMed ID: 37266828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients.
    Fischer A; Ousdigian KT; Johnson JW; Gillberg JM; Wilkoff BL
    Heart Rhythm; 2012 Jan; 9(1):24-31. PubMed ID: 21835150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discriminatory therapy for very fast ventricular tachycardia in patients with implantable cardioverter defibrillators.
    Sivagangabalan G; Eshoo S; Eipper VE; Thiagalingam A; Kovoor P
    Pacing Clin Electrophysiol; 2008 Sep; 31(9):1095-9. PubMed ID: 18834458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a programming algorithm for the third tachycardia zone in a fourth-generation implantable cardioverter-defibrillator.
    Neglia JJ; Krol RB; Giorgberidze I; Mathew P; Lewis C; Munsif AN; Saksena S
    J Interv Card Electrophysiol; 1997 Feb; 1(1):49-56. PubMed ID: 9869951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease.
    Wathen MS; Sweeney MO; DeGroot PJ; Stark AJ; Koehler JL; Chisner MB; Machado C; Adkisson WO;
    Circulation; 2001 Aug; 104(7):796-801. PubMed ID: 11502705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential role of antitachycardia pacing alerts for the reduction of emergency presentations following shocks in patients with implantable cardioverter-defibrillators: implications for the implementation of remote monitoring.
    Boulé S; Ninni S; Finat L; Botcherby EJ; Kouakam C; Klug D; Marquié C; Brigadeau F; Lacroix D; Kacet S; Guédon-Moreau L
    Europace; 2016 Dec; 18(12):1809-1817. PubMed ID: 26711741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of signal analyses of ventricular tachycardia electrograms to predict the response of antitachycardia pacing in patients with implantable cardioverter-defibrillators.
    Tuan TC; Lo MT; Lin YJ; Hsieh WH; Lin C; Huang NE; Lo LW; Chao TF; Liao JN; Hsieh YC; Wu TJ; Chen SA
    J Cardiovasc Electrophysiol; 2014 Apr; 25(4):411-417. PubMed ID: 24320556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of ENHANCED Implantable Cardioverter Defibrillator Programming to Reduce Therapies and Improve Quality of Life (from the ENHANCED-ICD Study).
    Mastenbroek MH; Pedersen SS; van der Tweel I; Doevendans PA; Meine M
    Am J Cardiol; 2016 Feb; 117(4):596-604. PubMed ID: 26732419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants.
    Fromer M; Brachmann J; Block M; Siebels J; Hoffmann E; Almendral J; Ohm OJ; den Dulk K; Coumel P; Camm AJ
    Circulation; 1992 Aug; 86(2):363-74. PubMed ID: 1638705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ventricular tachycardia in cardiolaminopathy: Characteristics and considerations for device programming.
    Sidhu K; Han L; Picard KCI; Tedrow UB; Lakdawala NK
    Heart Rhythm; 2020 Oct; 17(10):1704-1710. PubMed ID: 32454220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitachycardia pacing success in implantable cardioverter-defibrillators by patient, device, and programming characteristics.
    Sterns LD; Auricchio A; Schloss EJ; Lexcen D; Jacobsen L; DeGroot P; Molan A; Kurita T
    Heart Rhythm; 2023 Feb; 20(2):190-197. PubMed ID: 36272710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of antitachycardia pacing in patients with implantable cardioverter defibrillators and severely depressed left ventricular function.
    Heisel A; Neuzner J; Himmrich E; Pitschner HF; Liebrich A; Jung J; Sen S
    Pacing Clin Electrophysiol; 1995 Jan; 18(1 Pt 2):137-41. PubMed ID: 7724387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitachycardia pacing and low-energy cardioversion for ventricular tachycardia termination: a clinical perspective.
    Estes NA; Haugh CJ; Wang PJ; Manolis AS
    Am Heart J; 1994 Apr; 127(4 Pt 2):1038-46. PubMed ID: 8160578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Antitachycardia Pacing or Shocks With Survival in 69,000 Patients With an Implantable Defibrillator.
    Strickberger SA; Canby R; Cooper J; Coppess M; Doshi R; John R; Connolly AT; Roberts G; Karst E; Daoud EG
    J Cardiovasc Electrophysiol; 2017 Apr; 28(4):416-422. PubMed ID: 28128491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience with a third-generation implantable cardioverter-defibrillator.
    Saksena S; Mehta D; Krol RB; Tullo NG; Saxena A; Kaushik R; Neglia J
    Am J Cardiol; 1991 Jun; 67(16):1375-84. PubMed ID: 2042568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of intrinsic antitachycardia pacing for ventricular tachycardia refractory to conventional burst pacing: A case series.
    Kamakura T; Ueda N; Wada M; Ishibashi K; Kusano K
    J Cardiovasc Electrophysiol; 2023 Jan; 34(1):225-228. PubMed ID: 36511471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Termination and acceleration of ventricular tachycardia with autodecremental pacing, burst pacing, and cardioversion in patients with an implantable cardioverter defibrillator. Multicenter PCD Investigator Group.
    Hammill SC; Packer DL; Stanton MS; Fetter J
    Pacing Clin Electrophysiol; 1995 Jan; 18(1 Pt 1):3-10. PubMed ID: 7700828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival After Implantable Cardioverter-Defibrillator Shocks.
    Aktaş MK; Younis A; Zareba W; Kutyifa V; Klein H; Daubert JP; Estes M; McNitt S; Polonsky B; Goldenberg I
    J Am Coll Cardiol; 2021 May; 77(20):2453-2462. PubMed ID: 34016257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.